# 507543552 10/13/2022

## PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1 Stylesheet Version v1.2

EPAS ID: PAT7590444

	Name Execution Date	
CONVEYING PARTY DATA		
SEQUENCE:	2	
NATURE OF CONVEYANCE:	ASSIGNMENT	
SUBMISSION TYPE:	NEW ASSIGNMENT	

#### **RECEIVING PARTY DATA**

Name:	NUVALENT, INC.	
Street Address:	ONE BROADWAY, 14TH FLOOR	
City:	CAMBRIDGE	
State/Country:	MASSACHUSETTS	
Postal Code:	02142	

#### **PROPERTY NUMBERS Total: 1**

Property Type	Number
Application Number:	17834135

#### **CORRESPONDENCE DATA**

Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.Phone:6507393939Email:DebbieWu@JonesDay.com, WTokmakidis@JonesDay.comCorrespondent Name:JONES DAYAddress Line 1:250 VESEY STREET	Fax Number:	(650)739-3900	
Email:DebbieWu@JonesDay.com, WTokmakidis@JonesDay.comCorrespondent Name:JONES DAYAddress Line 1:250 VESEY STREET			
Correspondent Name:JONES DAYAddress Line 1:250 VESEY STREET	Phone:	6507393939	
Address Line 1: 250 VESEY STREET	Email:	DebbieWu@JonesDay.com, WTokmakidis@JonesDay.com	
	Correspondent Name:	JONES DAY	
	Address Line 1:	250 VESEY STREET	
Address Line 4: NEW YORK, NEW YORK 10281-104/	Address Line 4:	NEW YORK, NEW YORK 10281-1047	

ATTORNEY DOCKET NUMBER:	14709-016-999
NAME OF SUBMITTER:	DEBBIE WU
SIGNATURE:	/Debbie Wu/
DATE SIGNED:	10/13/2022

#### **Total Attachments: 5**

source=14709-001 PRI and PCT EXECUTED Assignment (PharmaResources to Nuvalent)#page1.tif source=14709-001 PRI and PCT EXECUTED Assignment (PharmaResources to Nuvalent)#page2.tif source=14709-001 PRI and PCT EXECUTED Assignment (PharmaResources to Nuvalent)#page3.tif source=14709-001 PRI and PCT EXECUTED Assignment (PharmaResources to Nuvalent)#page4.tif source=14709-001 PRI and PCT EXECUTED Assignment (PharmaResources to Nuvalent)#page4.tif ATTY. DOCKET NO.: NVX-00328 (PHARMARESOURCES CO., LTD. TO NUVALENT, INC.) PAGE 1 OF 3

#### ASSIGNMENT

This Assignment is made as of the <u>18</u> day of <u>October</u>, 2021, by and between **PharmaResources Co., Ltd.**, a corporation having its principal place of business at Building 2, No. 509, Renqing Road, Pudong New Area, Shanghal, China, ("ASSIGNOR") and **Nuvalent**, Inc., a Company having a place of business at One Broadway, 14<sup>th</sup> Floor, Cambridge, Massachusetts 02142, USA ("ASSIGNEE").

WHEREAS ASSIGNOR, owns the rights, title, and interest in International Patent Application No. PCT/US2021/030842, filed May 5, 2021; U.S. Provisional Application No. 63/125,733, filed December 15, 2020; and International Patent Application No. PCT/CN2020/088590, filed May 5, 2020; entitled "HETEROAROMATIC MACROCYCLIC ETHER CHEMOTHERAPEUTIC AGENTS";

together with any divisional, continuation, continuation-in-part, reissue, re-examination, renewal or extension thereof and any patent issuing therefrom, and any corresponding patent, utility model, inventor certificate, registration or the like in any country of the world with respect to the foregoing, (the "Inventions"), having full right to convey its entire right, title and interest, both legal and equitable, in and to said inventions, free from all prior assignments, agreements, licenses, mortgages, security interests, or other encumbrances whatsoever; and

WHEREAS ASSIGNEE is desirous of acquiring the entire right, title and interest in and to said Inventions and any and all patents to be obtained therefor;

NOW, THEREFORE, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, ASSIGNOR and ASSIGNEE hereby agree as follows:

Assignment of Inventions. ASSIGNOR does hereby sell, assign, transfer and set 1. over unto ASSIGNEE, its successors and assigns, its entire right, title and interest throughout the world in and to: (i) said Inventions, and any form or embodiment thereof; (ii) all contracts, licenses, assignments and agreements of any kind or nature arising from such Inventions, including, without limitation all agreements with any inventor who has contributed to the Inventions; (iii) all proprietary rights pertaining to the Inventions including, without limitation, all rights arising from or relating to copyright, patent, trade secret, data and any rights arising under any laws now or hereinafter enacted relating to data protection, and all other proprietary rights of any kind or nature, now existing or hereafter created, however denominated, throughout the world; (iv) all claims and causes of action arising from or relating to the Inventions, including, without limitation, any and all claims or causes of action arising from or relating to the above described contracts and proprietary rights, whether arising in the past, present or future; (v) any application filed in any country based on the Invention, including the right to file said applications and claim priority under the provisions of any international convention or treaty; and (vi) the entire right, title and interest throughout the world in and to any and all patents or re-examinations or reissues or extensions thereof to be obtained in any country upon said Inventions and any divisionals, continuations, continuations-in-part and renewals thereof, or substitute applications therefor, and all applications for industrial property protection, including, without limitation, all applications for patents, utility models, and designs which may hereafter be filed for an Invention described in any

FH10238266.2

## PATENT REEL: 061419 FRAME: 0055

#### ATTY. DOCKET NO.: NVX-00328 (PHARMARESOURCES CO., LTD. TO NUVALENT, INC.) PAGE 2 OF 3

of the foregoing applications, including pending and abandoned applications, in any country or countries of the world, together with the right to file such applications and the right to claim for the same the priority rights derived from said applications under the Patent Laws of the United States, the International Convention for the Protection of Industrial Property, or any other international agreement or the domestic laws of the country in which any such application is filed, as may be applicable. The undersigned hereby authorizes and requests the issuing authority to issue any and all patents on said application or applications to said ASSIGNEE or its successors and assigns.

Further Assurances. ASSIGNOR further agrees, without any further payment or 2. compensation by ASSIGNEE or its successors and assigns, to assign, deliver and communicate to ASSIGNEE, its representatives or agents or its successors and assigns, any know-how, facts, and materials arising from or relating to said Inventions including without limitation: (i) all biological material, transgenic animals, and other embodiments of the Inventions; (ii) all drawings, blueprints, calculations, research plans and results, lab notes, workbooks, and other records and written materials that relate to the Inventions or the Application or that embody or record any know-how pertaining to the Inventions; (iii) all files, documents and communications pertaining to the Application, including, without limitation, all communications to and from the U.S. Patent and Trademark Office and any and all legal counsel advising on or assisting with the Application; and (iv) evidence for interference or purposes or for other legal proceedings whenever requested. The undersigned further agrees to testify in any interference or or other legal proceedings, whenever requested; to execute and deliver, on request, all lawful papers required to make any of the foregoing provisions effective; and generally do everything reasonable to aid said ASSIGNEE, its successors or assigns and nominees to secure, obtain and enforce proper patent protection for said invention or inventions in any country.

FH10238266.2

### PATENT REEL: 061419 FRAME: 0056

#### ATTY. DOCKET NO.: NVX-00328 (PHARMARESOURCES CO., LTD. TO NUVALENT, INC.) PAGE 3 OF 3

IN WITNESS WHEREOF, PharmaResources Co., Ltd., ASSIGNOR, by its duly authorized officer, has caused this Assignment to be executed under witness this 1346 day of 1000 day of 2021.

	Jung +	
Print Name	Tiang Shenghi	*
Title:	Deputy General Man	ager
(	Quin G	V

Witness signature

Qiuli Li Witness Name (please print)

won Thank

Witness signature

Min Zhang Witness Name (please print)

IN WITNESS WHEREOF, Nuvalent, Inc., ASSIGNEE, by its duly authorized officer, has caused this Assignment to be executed under witness this \_\_\_\_\_\_ day of \_\_\_\_\_\_, 2021.

Print Name:

Title:

Witness signature

Witness Name (please print)

PATENT REEL: 061419 FRAME: 0057

FH10238266.2

ATTY, DOCKET NO.: NVX-00328 (PHARMARESOURCES CO., LTD. TO NUVALENT, INC.) PAGE 3 OF 3

IN WITNESS WHEREOF,	PharmaResources Co., Ltd., ASSIGNOR, by its duly
authorized officer, has caused this As	ssignment to be executed under witness this $12.4$ day of
7 crie ber, 2021.	>

Print Name: Title: desidentes Witness signature Qiuli Li Witness Name (please print)

ion thang

Witness signature

Min Zhang Witness Name (please print)

IN WITNESS WHEREOF, Nuvalent, Inc., ASSIGNEE, by its duly authorized officer, has caused this Assignment to be executed under witness this \_//\_\_\_\_\_ day of \_///2/2/\_\_\_\_\_\_ 2024.

Print Name: Dr. Lor, L. A. Hills

Title: Chief Legal Officer

(see notarization, next page)

Witness signature

Witness Name (please print)

FH10238266.2

## PATENT REEL: 061419 FRAME: 0058



#### NOTARY CERTIFICATION

COMMONWEALTH OF MASSACHUSETTS: ) ) SS .: COUNTY OF Middleser : )

On this <u>11</u> day of <u>March</u>, 2023 before me, the undersigned Notary Public, personally appeared <u>Deborah H-Miller</u>, and proved to me through satisfactory evidence of identification, which were <u> $Delonal Knaule dee}$ </u>, to be the person whose named is signed on the preceding or attached document, and acknowledged to me that he/she signed it voluntarily for its stated purpose.</u>

ula Chula

Paula Chubet Notary Public Commonwealth of Massachusetts

My Commission Expires: September 06, 2024



**RECORDED: 10/13/2022**